Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology ( (HK:9966) ) has issued an update.
Alphamab Oncology announced that all proposed resolutions at their Annual General Meeting on June 12, 2025, were approved by shareholders. Key resolutions included the approval of financial statements, granting mandates for share repurchase and issuance, and the re-election of directors, indicating strong shareholder support and potentially enhancing the company’s strategic flexibility and governance.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the research, development, and commercialization of innovative cancer therapies. The company operates within the oncology sector, aiming to provide advanced treatment options for cancer patients.
Average Trading Volume: 4,140,755
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.01B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.